The reassessment of Leqembi’s safety data follows the agency’s previous recommendation of the drug for use in the EU.

Children who inherit genetic mutations from parents with early-onset Alzheimer’s typically show signs of dementia at the same ...

The FDA has approved the sBLA for once every 4 weeks lecanemab-irmb (Leqembi®) intravenous maintenance dosing.

Verywell Health's content is for informational and educational purposes only. Our website is not intended to be a substitute ...

Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment Alzheimer's ...

The FDA has approved the sBLA of Eisai and Biogen's LEQEMBI for maintenance dosing indicated for the early stages of ...

We now have two FDA-approved disease-modifying treatments for Alzheimer's disease, and hundreds of clinical trials are ...

Approval was based on results from multiple studies, which demonstrated a slowing of cognitive decline in patients with ...

The European Commission has requested its medicines regulator to consider safety information on Eisai and Biogen's ...

Alzheimer’s disease progression does not stop after plaque clearance; ongoing treatment with LEQEMBI can slow disease progression and prolong the benefits of therapy TOKYO and CAMBRIDGE, Mass., Jan.